+39 02 610346.1 - info@newron.com

Latest press releases

  • 26Feb
    Parkinson’s disease (PD): EU Commission approves Xadago® (safinamide) for mid-late stage PD patients

  • 5Feb
    Newron to Present at the 17th Annual BIO CEO & Investor Conference and the Leerink Global Healthcare Conference

  • 15Jan
    Newron initiates Phase II study of sNN0029 in patients with Amyotrophic Lateral Sclerosis


  • 15Jan
    Newron announces results of Phase I study of NW-3509; Phase II study in schizophrenia patients planned for Q2 2015


  • 14Jan
    Newron initiates Phase II study of sNN0031 in patients with Parkinson’s disease


  • 29Dec
    Safinamide New Drug Application (NDA) Re-submitted to the US Food and Drug Administration (FDA)


View All

Newron share price


  • 20May
    Bio€quity Europe

    May 19-20, 2015 - InterContinental Vienna Hotel, Vienna - Austria

  • 14Apr
    Swiss Biotech Day

    April 14, 2015 - Congress Center Basel, Hall 4, Basel -Switzerland

  • 10Mar
    27th Annual ROTH Conference

    March 8-11, 2015 - The Ritz-Carlton, Dana Point, CA - US

View Event Calendar